Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Curative Prevention and Treatment for Hepatocellular Carcinoma
share announcement

Curative Prevention and Treatment for Hepatocellular Carcinoma

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: closed (15 June 2023) | Viewed by 2625

Special Issue Editor

Dr. Katsunori Yoshida

E-Mail Website
Guest Editor
Department of Gastroenterology and Hepatology, Kansai Medical University, Osaka 573-1191, Japan
Interests: TGF-b; Smad; liver fibrosis; HCC; PBC; viral hepatitis

Special Issue Information

Dear Colleagues,

Hepatocellular carcinoma (HCC) is a highly prevalent malignant tumor, which usually develops in patients with chronic liver disease. The prognosis of HCC at an early stage has improved considerably in recent years. However, the prognosis of unresectable advanced HCC is still unsatisfactory. The MAPK and PI3K cascades, which are signaling pathways responsible for inhibition of cell proliferation, angiogenesis, or cell death, are characterized by the presence of tyrosine kinase activity at the upstream receptors for growth factors, and many molecular targeted therapies are designed to inhibit tyrosine kinase activity. In particular, recently, VEGF inhibitors have been used to inhibit the activity of angiogenesis of HCC. In particular, the recent emergence of VEGF inhibitors and immune checkpoint inhibitors has improved the prognosis of advanced liver cancer, although it is still limited to cirrhotic patients with Child–Pugh classification A (good liver function). Molecular targeted therapy for liver cancer has just begun, and there are various issues that need to be resolved. One example is the identification of biomarkers to confirm the safety of long-term administration and to predict the therapeutic effect. In addition, further elucidation of the mechanism of hepatocarcinogenesis and development of more specific molecular targeted therapeutics are also awaited.

Dr. Katsunori Yoshida
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • hepatocellular carcinoma
  • liver cancer
  • MAPK
  • PI3K
  • VEGF inhibitors

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

11 pages, 1858 KiB  
Article
Predictive Power of the Albumin–Bilirubin Score for Hepatotoxicity in Stereotactic Ablative Radiation Therapy for Hepatocellular Carcinoma
by Jihyeon Joo, Hosang Jeon, Dongwoon Kim, Wontaek Kim, Jiho Nam, Donghyun Kim, Dahl Park, Choongrak Kim and Yongkan Ki
Cancers 2023, 15(15), 3777; https://doi.org/10.3390/cancers15153777 - 25 Jul 2023
Cited by 1 | Viewed by 857
Abstract
Assessment of liver function is crucial in predicting treatment outcomes for hepatocellular carcinoma (HCC). This study aimed to evaluate the prognostic performance of the albumin–bilirubin (ALBI) score for predicting hepatotoxicity following stereotactic body radiation therapy (SBRT) in HCC patients. A retrospective analysis was [...] Read more.
Assessment of liver function is crucial in predicting treatment outcomes for hepatocellular carcinoma (HCC). This study aimed to evaluate the prognostic performance of the albumin–bilirubin (ALBI) score for predicting hepatotoxicity following stereotactic body radiation therapy (SBRT) in HCC patients. A retrospective analysis was conducted on 123 HCC cases treated between 2018 and 2020. ALBI and Child-Turcotte-Pugh (CTP) scores were calculated, and hepatotoxicity was defined as a post-SBRT CTP score increase ≥2. Receiver operating characteristic (ROC) curves were used for comparison. The optimal cutoff value of the ALBI score was determined. Among the 121 patients analyzed, hepatotoxicity occurred in 5%. The ALBI score showed better predictive accuracy (area under the ROC curve: 0.77) than the CTP score. The optimal cutoff value of the ALBI score was −2.47, with a sensitivity of 85.7% and a specificity of 71.1%. Multivariable analysis revealed that ALBI score and PTV were significant factors for hepatotoxicity. In conclusion, the ALBI score demonstrated prognostic value for hepatotoxicity prediction after SBRT in HCC patients. Considering the ALBI score and PTV provides valuable insights for assessing hepatotoxicity risk during SBRT treatment for HCC. Full article
(This article belongs to the Special Issue Curative Prevention and Treatment for Hepatocellular Carcinoma)
►▼ Show Figures

Figure 1

11 pages, 1119 KiB  
Article
The Benefits of Radical Treatments with Synchronous Splenectomy for Patients with Hepatocellular Carcinoma and Portal Hypertension
by Qikun Zhang, Qi Li, Fuchao Shang, Guangming Li and Menglong Wang
Cancers 2022, 14(13), 3155; https://doi.org/10.3390/cancers14133155 - 28 Jun 2022
Viewed by 1359
Abstract
Background: The survival benefits of radical treatment (resection or radiofrequency ablation) combined with splenectomy for primary hepatocellular carcinoma (HCC) in patients with liver-cirrhosis-associated portal hypertension (PH) remain to be clarified. Methods: 96 patients undertaking HCC radical treatment combined with splenectomy (HS group) were [...] Read more.
Background: The survival benefits of radical treatment (resection or radiofrequency ablation) combined with splenectomy for primary hepatocellular carcinoma (HCC) in patients with liver-cirrhosis-associated portal hypertension (PH) remain to be clarified. Methods: 96 patients undertaking HCC radical treatment combined with splenectomy (HS group) were retrospectively analyzed, 48 of whom belonged to HCC stage T1 (HSS group). Another 42 patients at stage T1 with PH who received hepatectomy (or radiofrequency ablation) alone (HA group) during the same period served as the control group. Recurrence-free survival (RFS) and overall survival (OS) were compared at each time point between the HSS and HA group. The risk factors affecting early RFS and OS were confirmed through COX multivariate analysis. Results: The median RFS was 22.3 months and the mean median OS was 46 months in the HS group. As such, 1-year, 2-year, 3-year, and 5-year RFS rates in the HSS and HA group were 95% and 81% (p = 0.041), 81% and 67% (p = 0.05), 64% and 62% (p = 1.00), and 29% and 45% (p = 0.10), respectively. Further, 1-year, 3-year, and 5-year OS rates in the HSS and HA group were 98% and 98% (p = 1.00), 79% and 88% (p = 0.50), and 60% and 64% (p = 0.61), respectively. Cox multivariate analysis showed that preoperative irregular anti-viral therapy, Child-Pugh grade B liver function, vascular invasion, and microvascular invasion (MVI) were independent risk factors for early postoperative RFS (within 2 years), and preoperative irregular anti-viral therapy and vascular invasion were independent risk factors for 5-year OS. Conclusions: Radical treatment of HCC combined with synchronous splenectomy, especially applicable to patients with Child-Pugh grade A liver function, can significantly improve early postoperative RFS in patients with stage T1 HCC and liver-cirrhosis-associated portal hypertension, but fail to improve OS. Full article
(This article belongs to the Special Issue Curative Prevention and Treatment for Hepatocellular Carcinoma)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop